Intravenous ofatumumab treatment of multiple sclerosis and related disorders: An observational studySahla El Mahdaoui, Finn Sellebjerg, Jeppe Romme Christensen et al.|Multiple Sclerosis and Related Disorders|2022Cited by 7
Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)—an individual participant data meta-analysisLisa G Schoof, Jeppe Romme Christensen, Einar August Høgestøl et al.|Multiple Sclerosis and Related Disorders|2025Cited by 3